Repros Therapeutics (NASDAQ:RPRX), one of the best performing biotech stocks of 2012, is developing Androxal for the treatment of secondary hypogonadism. The profit potential in this space is huge, given that the current market leader -- AbbVie's Androgel -- raked in a whopping $1.19 billion in 2012.

Shares of Repros took a dramatic fall, however, after a company press release indicated some anomalies in one of Androxal's key clinical trials. Healthcare analyst Max Macaluso breaks down this story in the following video.

 

Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.